{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"Adjuvant! is not currently available; additional work combining classical information with genomic tests will be reported separately.","groups":[{"description":"Group 1 (Oncotype DX recurrence score =\\< 10): Patients in this group receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"OG000","title":"Arm A"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive hormone therapy with tamoxifen, anastrozole, letrozole, or exemestane PO for up to 5 years. Some patients then continue to receive hormone therapy for an additional 5 years.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO","id":"OG001","title":"Arm B"},{"description":"Group 2 (Oncotype DX recurrence score 11-25): Patients receive standard combination chemotherapy at the discretion of the treating physician. Within 4 weeks after the last dose of chemotherapy, patients receive hormonal therapy as in Group 1 at the discretion of the treating physician.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"OG002","title":"Arm C"},{"description":"Group 3 (Oncotype DX recurrence score \\>= 26): Patients in this group receive combination chemotherapy followed by hormone therapy similar to the patients in Group 2 who are assigned to receive both types of treatment.\n\nAnastrozole: Given PO Exemestane: Given PO Letrozole: Given PO Tamoxifen: Given PO\n\nCombination chemotherapy: including oral CMF, IV CMF, standard AC, dose dense AC, standard AC-T, dose dense AC-T, FEC, TAC, TC, other protocol-specified regimens if participating in other CTSU trials including chemotherapy, and other regimens not protocol-specified if not participating in CTSU trials","id":"OG003","title":"Arm D"}],"populationDescription":"Outcome will never be analyzed.","reportingStatus":"POSTED","timeFrame":"Assessed at 10 years after study entry","title":"To Compare the Outcomes Projected at 10 Years by Adjuvant! With Those Made by the Genomic Health Oncotype DX Test","type":"SECONDARY"}